323
Views
7
CrossRef citations to date
0
Altmetric
Review

Pharmacologic therapies for the management of non-neurogenic urinary incontinence in children

&
Pages 2335-2352 | Received 07 Jan 2019, Accepted 26 Sep 2019, Published online: 23 Oct 2019

References

  • Forsythe WI, Redmond A. Enuresis and spontaneous cure rate: study of 1129 enuretis. Arch Dis Child. 1974;49(4):259–263.
  • Van Herzeele C, Walle JV, Dhondt K, et al. Recent advances in managing and understanding enuresis. F1000Res. 2017 Oct 24;6: 1881
  • Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the international children’s continence society. J Urol. 2014;191(6):1863–1865.
  • Abbott SM, Reid KJ, Zee PC. Circadian rhythm sleep-wake disorders. Psychiatr Clin North Am. 2015;38(4):805–823.
  • Dossche L, Wall JV, Van Herzeele C. The pathophysiology of monosymptomatic nocturnal enuresis with special emphasis on the circadian rhythm of renal physiology. Eur J Pediatr. 2016;175(6):747–754.
  • Caldwell PH, Edgard D, Hodson E, et al. Bedwetting and toileting problems in children. Med J Aust. 2005;182(4):190–195.
  • Kahraman A, Dursun H, Hatipoglu S, et al. Non-dipping phenomenon in children with monosymptomatic nocturnal enuresis. Pediatr Nephrol. 2013;28(7):1099–1103.
  • Caldwell PH, Sureshkumar P, Wong WC. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev. 2016 Jan 20;1:CD002117.
  • Vande Walle J, Stockner M, Raes A, et al. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007;2(3):232–238.
  • Juul KV, Van Herzeele C, De Bruyne P, et al. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 2013;172(9):1235–1242.
  • Franco I, von Gontard A, De Gennaro M. International children’s continence society. Evaluation and treatment of monosymptomatic enuresis: a standardization document from the international children’s continence society. J Pediatr Urol. 2013;9(2):239–243.
  • Rang and Dali’s pharmacology, 7thed. 399–400. Edinburgh:Elsevier/Churchill Livingstone; 2011.
  • Richardson DW, Robinson AG. Desmopressin. Ann Intern Med. 1985 Aug;103(2):228–239.
  • Highlights of prescribing information. Desmopressin Acetate. [cited 2019 May 10]. Available from: https://pdf.hres.ca/dpd_pm/00033156.PDF
  • Callreus T, Lundahl J, Hoglund P, et al. Changes in the gastrointestinal motility influence the absorption of desmopressin. Eur J Clin Pharmacol. 1999;55(4):305–309.
  • De Guchtenaere A, Van Herzeele C, Raes A, et al. Oral lyophilizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol. 2011;185(6):2308–2313.
  • Michelet R, Dossche L, De Bruyne P, et al. Effects of food and pharmaceutical formulation on desmopressin in pharmacokinetics in children. Clin Pharmacokinet. 2016;55(6):1159–1170.
  • Michelet R, Dossche L, Van Herzeele C, et al. Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis. Eur J Clin Pharmacol. 2018;74(3):297–305.
  • Skoog SJ, Stokes A, Turner KL. Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis. J Urol. 1997;158(3 pt 2):1035–1040.
  • Schulman SL, Stokes A, Salzman PM. The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis. J Urol. 2001;166(6):2427–2431.
  • Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane DataBase Syst Rev. 2002;(3):CD002112.
  • Chua ME, Silangcruz JM, Chang SJ, et al. Desmopressin withdrawal strategy for pediatric enuresis: A meta- analysis. Pediatrics. 2016;138(1):pii:e20160495. Epub 2016 Jun 24.
  • Rushton HG. Older pharmacologic therapy for nocturnal enuresis. Clin Pediatr (Phila). 1993 Jul; Spec No: 10–3
  • Deshpande AV, Caldwell PH. Medical management of nocturnal enuresis. Pediatr Drugs. 2012. 1. 14(2):71–77.
  • Neveus T, Eggert P, Evans J, et al. International children’s continence society. evaluation and treatment of monosymptomatic enuresis: a standardization document from the international children’s continence society. J Urol. 2010;183(2):441–447.
  • Bayne AP, Skoog SJ. Nocturnal enuresis: an approach to assessment and treatment. Pediatr Rev. 2014;35(8):327–334.
  • Skoog SJ. Nocturnal enuresis: an approach to assessment and treatment. Pediatr Rev. 2014;35:327.
  • Hunsballe JM, Rittig S, Pedersen EB, et al. Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria. J Urol. 1997;158(3pt1):830–836.
  • Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19(3):373–409.
  • DeVane CL, Savett M, Jusko WJ. Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers. Eur J Clin Pharmacol. 1981;19(1):61–64.
  • Pollock BG, Perel JM. Hydroxy metabolites of tricyclic antidepressants: evaluation of relative cardiotoxicity. Psychopharmacol. 1989;7:232–236.
  • Potter WZ, Manji HK. Antidepressants, metabolites, and apparent drug resistance. Clin Neuropharmacol. 1990;13(Suppl 1):S45–53.
  • Smellie JM, McGrigor VS, Meadow SR, et al. Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs. Arch Dis Child. 1996;75(1):62–66.
  • Prescribing information imipramine. [cited 2019 Sep 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040903lbl.pdf
  • Austin PF, Ferguson G, Yan Y, et al. Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial. Pediatr. 2008;122(5):1027–1032.
  • Park SJ, Park JM, Pai KS, et al. Desmopressin alone versus desmopressin and an anticholinergic in the first line treatment of primary monosymptomatic nocturnal enuresis: A multicenter study. Pediatr Nephrol. 2014;29(7):1195–1200.
  • Kazemi Rashed F, Nourizade D, Hajebrahimi S, et al. Does combination therapy with desmopressin and tolterodine improve the treatment outcomes of patients with monosymptomatic nocturnal enuresis? A randomized clinical controlled trial. ISRN Urol. 2013 Mar 25;2013:413146.
  • Berkenwald A, Pires J, Ellsworth P. Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis. J Pediatr Urol. 2016;12(4):220.e1-6.
  • Azarfar A, Esmaeili M, Naseri M, et al. Comparison of combined treatment with desmopressin plus oxybutynin and desmopressin plus tolterodine in treatment of children with primary nocturnal enuresis. J Renal Injury Prev. 2015;4(3):80–86.
  • Neveus T, Tullus K. Tolterodine and imipramine in refractory enuresis: a placebo-controlled crossover study. Pediatr Nephrol. 2008;23(2):263–267.
  • Kajiwara M, Inoue K, Kato M, et al. Nocturnal enuresis and overactive bladder in children: an epidemiologic study. Int J Urol. 2006;13(1):36–41.
  • Chung JM, Lee SD, Kang DI, et al. Prevalence and associated factors of overactive bladder in Korean children 5–13 years old: A nationwide multicenter study. Urology. 2009;73:63–67.
  • Franco I. Overactive bladder in children. Nat Rev Urol. 2016 Sep;13(9):520–532. Epub 2016 Aug 17.
  • Veiga ML, Lordêlo P, Farias T, et al. Constipation in children with isolated overactive bladders. J Pediatr Urol. 2013;9(6 pt A):L 945–9.
  • Ramsay S, Bolduc S. Overactive bladder in children. Can Urol Assn J. 2017;11(1–2 suppl 1):S74–S79.
  • Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med. 2019 Jun 24;179: 1084.
  • Prescribing information, oxybutynin. [cited 2019 Sept 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017577s034,018211s017,020897s018lbl.pdf
  • Van Arendonk KJ, Knudson MJ, Austin JC, et al. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. Urology. 2006;68(4):862–865.
  • Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology. 2002;59(3):428–432.
  • Reinberg Y, Crocker J, Wolpert J, et al. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. J Urol. 2003;169(1):317–319.
  • Gleason JM, Daniels C, Williams K, et al. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive well tolerated alternative form of administration. J Pediatr Urol. 2014;10(4):753–757.
  • Solifenacin pediatric data. [cited 2019 Sept 23]. Available from: https://www.fda.gov/media/107501/download
  • Bolduc S, Moore K, Nadeau G, et al. Prospective open label study of solifenacin for overactive bladder in children. J Pediatr Urol. 2010;184(4 suppl):1668–1673.
  • Nadeau G, Schroder A, Moore K, et al. Long-term use of solifenacin in pediatric patients with overactive bladder: extension of a prospective open-label study. Can Urol Assoc J. 2014;8(3–4):118–123.
  • Hoebeke P, De Pooter J, De Caestecker K, et al. Solifenacin for therapy resistant overactive bladder. J Urol. 2009;182(4 Suppl):2040–2044.
  • Newgreen D, Bosman B, Hollestein-Havelaar A, et al. Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol. 2017;71(3):483–490.
  • Newgreen D, Bosman B, Hollestein-Havelaar A, et al. Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder. J Urol. 2017;198(4):928–936.
  • Lee SD, Chung JM, Kang DI, et al. Efficacy and tolerability of solifenacin 5mg fixed dose in Korean children with newly diagnosed idiopathic overactive bladder: a multicenter prospective study. J Korean Med Sci. 2017;32(2):329–334.
  • Detrol LA NDA. FDA. [cited 2019 Sept 23]. Available from: https://www.fda.gov/media/92542/download
  • Nijman RJ, Borgstein NG, Ellsworth P, et al. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo-controlled trials. J Urol. 2005;173(4):1334–1339.
  • Kilic N, Balkan E, Akgoz S, et al. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Int J Urol. 2006;13(2):105–108.
  • Deng YJ, Ma G, Guo YF, et al. Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder. Zhongguo Dang Dai Er Ke Za Zhi. 2011;13(1):26–28.
  • Babu R. Effectiveness of tolterodine in nonneurogenic voiding dysfunction. Indian Pediatr. 2006;43(11):980–983.
  • Hjalmas K, Hellstrom AL, Mogren K, et al. The overactive bladder in children: a potential future indication for tolterodine. BJU Int. 2001;87(6):569–574.
  • Munding M, Wessells H, Thornberry B, et al. Use of tolterodine in children with dysfunctional voiding: an initial report. J Urol. 2001;165(3):926–928.
  • Reinberg Y, Crocker J, Wolpert J, et al. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. J Urol. 2003;169(1):317–319.
  • Raes A, Hoebeke P, Segaert I, et al. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder. Eur Urol. 2004;45(2):240–244.
  • Goessl C, Sauter T, Michael T, et al. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology. 2000;55(3):414–418.
  • Ayan S, Kaya K, Topsakal K, et al. Efficacy of tolterodine as a first-line treatment for nonneurogenic voiding dysfunction in children. BJU Int. 2005;96(3):411–414.
  • Nijman RJ, Borgstein NG, Ellsworth P, et al. Long-term tolerability of tolterodine extended release in children 5–11 years of age: results from a 12-month, open-label study. Eur Urol. 2007;52(5):1511–1516.
  • Ayan S, Topsakal K, Gokce G, et al. Efficacy of combined anticholinergic treatment and behavioral modification as a first line treatment for nonneurogenic and nonanatomical voiding dysfunction in children: a randomized controlled trial. J Urol. 2007;177(6):2325–2328.
  • Mahanta K, Medhi B, Kaur B, et al. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. J Pediatr Urol. 2008;4(2):118–123.
  • Lopez Pereira P, Miguelez C, Caffarati J, et al. Trospium chloride for the treatment of detrusor instability in children. J Urol. 2003;170(5):1978–1981.
  • Malhotra B, El-Tahtawy A, Wang EQ, et al. Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder. J Pediatr Urol. 2012;8:336342.
  • Blais AS, Nadeau G, Moore K, et al. Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70(1):9–13.
  • Leon P, Jolly C, Binet A, et al. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children. J Pediatr Surg. 2014;49(9):1424–1428.
  • Hoebeke P, De Caestecker K, Vande Walle J, et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol. 2006;176(1):328–331.
  • Blackburn SC, Jones C, Bedoya S, et al. Intravesical botulinum type-A toxin (Dysport) in the treatment of idiopathic detrusor overactivity in children. J Pediatr Urol. 2013;9(6 Pt A):750–753.
  • Marte A, Borrelli M, Sabatino MD, et al. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children. Eur J Pediatr Surg. 2010;20(3):153–157.
  • Ucar M, Akgul AK, Parlak A, et al. Non-invasive evaluation of botulinum-A toxin treatment efficacy in children with refractory overactive bladder. Int Urol Nephrol. 2018;50(8):1367–1373.
  • Bayrak O, Sadioglu E, Sen H, et al. Efficacy of onabotulinum toxin A infection in pediatric patients with non-neurogenic detrusor overactivity. Neurourol Urodyn. 2017;36(8):2078–20782.
  • Lahdes-Vasama TT, Anttila A, Wahl E, et al. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. Scan J Urol Nephrol. 2011;45(6):397–400.
  • Greer T, Abbott J, Breytenbach W, et al. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. J Pediatr Urol. 2016;12(2):94.e1–6.
  • De Jonge GA. Enuresis risoria (giggle micturition). Ned Tijdschr Geneeskd. 1975;119:1335–1338.
  • Logan BL, Blais S. Giggle incontinence: evolution of concept and treatment. J Pediatr Urol. 2017;13(5):430–435.
  • Leclair MD, Heloury Y. Non-neurogenic elimination disorders in children. J Pediatr Urol. 2010;6(4):338–345.
  • Cooper C. Giggle micturition. In: Kolvin I, Mackeith RC, Meadow SR, editors. Bladder control and enuresis. clinics in developmental medicine, No. 48 and 49. London: William Heinemann Ltd; 1973. p. 61–65.
  • Berry AK, Zderic S, Carr M. Methylphenidate for giggle incontinence. J Urol. 2009;182(4 Suppl):2028–2032.
  • Azim E, Mobbs D, Jo B, et al. Sex differences in brain activation elicited by humor. Proc Natl Acad Sci USA. 2005 8;102(45):16496–16501.
  • Chandra M, Saharia R, Shi Q, et al. Giggle incontinence in children: a manifestation of detrusor instability. J Urol. 2002;168(5):2184–2187.
  • Palmer LS. Biofeedback in the management of urinary continence in children. Curr Urol Rep. 2010;11(2):122–127.
  • Elzinga-Plomp A, Boemers TM, Messer AP, et al. Treatment of enuresis risoria in children by self-administered electric and imaginary shock. Br J Urol. 1995;76(6):775–778.
  • Sher PK. Successful treatment of giggle incontinence with methylphenidate. Pediatr Neurol. 1994;10:81.
  • Sher PK, Reinberg Y. Successful treatment of giggle incontinence with methylphenidate. J Urol. 1996;156(2 Pt 2):656–658.
  • Prescribing information, Ritalin. [ cited 2019 Sep 23]. Available from: https://www.pharma.us.novartis.com/files/ritalin_ritalin-sr.pdf
  • Chang JH, Lee KY, Kim TB, et al. Clinical and urodynamic effect of methylphenidate for the treatment of giggle incontinence (enuresis risoria). Neurourol Urodyn. 2011;30(7):1338–1342.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.